

1 **Investigating sensitivity of nasal or throat (ISNOT): A combination of both swabs increases sensitivity**
2 **of SARS-CoV-2 rapid antigen tests**

3

4 Barbara L Goodall^a, Jason J LeBlanc^{a,b,c,d}, Todd F Hatchette^{a,b,c,d}, Lisa Barrett^{a,b,c,d}, *Glenn Patriquin^{a,b,c,d}

5

6 ^aDepartment of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

7 ^bDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.

8 ^cDivision of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health,

9 Halifax, Nova Scotia, Canada.

10 ^dDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.

11

12 **Key Words:** COVID-19, SARS-CoV-2, rapid, antigen, nasal, throat

13 **Running title:** Comparison of nasal and throat swabs for rapid antigen testing for SARS-CoV-2

14

15 **Word count:** 2706

16 ***Corresponding author:** Glenn Patriquin

17 Division of Microbiology, Department of Pathology and Laboratory

18 Medicine, Nova Scotia Health (NSH),

19 Room 315 MacKenzie Building,

20 5788 University Avenue, Halifax, Nova Scotia, B3H 1V8

21 Tel.: +1 902 473 7493, Fax: +1 902 473 6432

22 Email: glenn.patriquin@nshealth.ca

23

24 **Abstract**

25 The COVID-19 pandemic has been hallmarked by several waves of variants of concern (VoCs), each with
26 novel challenges. Currently, the highly transmissible Omicron VOC is predominant worldwide, and sore
27 throat is common among other cold-like symptoms. Anecdotes on social media suggested sampling one's
28 throat can increase sensitivity for Omicron detection by antigen-based rapid testing devices (Ag-RDTs).
29 This work determines whether the sensitivity of Ag-RDTs designed for nasal sampling is altered with use
30 of self-administered throat swabs in self-perceived asymptomatic individuals. This investigation compared
31 results of a common Ag-RDT (i.e. Abbott Panbio COVID-19 Ag Rapid Test Device) using three sampling
32 sites: nasal swab; throat swab and; combined nasal/throat. All Ag-RDT results were confirmed with
33 molecular testing. Compared to RT-PCR, samples from nasal or throat swabs each detected 64.5% of
34 SARS-CoV-2 cases; however, combining the contributions of each swab increased sensitivity to 88.7%.
35 This trend was also evident with the Rapid Response Ag-RDT (BTNX), which uses a more flexible swabs
36 than Panbio. When nasal swab collection was compared to paired sampling of the nasal/throat using a
37 single swab with the Panbio Ag-RDT, the sensitivity of each was 68.4% and 81.6%, respectively. No false-
38 positive results were observed with nasal, throat, or combined nasal/throat sampling. Self-administered
39 throat and nasal/throat swabs both had >90% acceptability. These findings support the use of self-
40 collected combined nasal/throat sampling for Ag-RDT based SARS-CoV-2 detection in self perceived
41 asymptomatic individuals.

42

43 **Introduction**

44 The COVID-19 pandemic is an ongoing threat to global public health. Since the first cases were reported
45 in December 2019, several SARS-CoV-2 variants concern (VoCs) have emerged, causing multiple waves of
46 infection globally¹. In the last 4 weeks, the predominant VoC in many jurisdictions is SARS-CoV-2 lineage
47 B.1.1.529, designated Omicron by the World Health Organization (WHO) classification working group¹,
48 which is highly mutated, with over 50 mutations compared to ancestral reference genomes^{2,3}. Most
49 mutations are present in the gene encoding spike, the protein that is targeted by all current vaccines, and
50 plays a role in host receptors interactions to facilitate viral entry and subsequent replication. Among other
51 Omicron mutations, four mutations are in the gene encoding nucleocapsid, the target of most antigen-
52 based rapid diagnostic tests (Ag-RDTs). While some recent data have alleviated initial concerns over the
53 possibility of decreased sensitivity of Ag-RDTs with Omicron, there are other noted differences from
54 previous VOCs⁴. Omicron has increased transmission, reduced vaccine effectiveness^{5,6}, and recent studies
55 have suggested there could be differences in tissue tropism^{3,7,8}.

56 Clinically prominent cold-like symptoms, especially marked sore throat⁹, combined with reports of
57 perceived decreased sensitivity of self-performed Ag-RDTs with bilateral nasal swab collection, have led
58 to anecdotal recommendations to self-swab one's throat (with or without nasal swabbing), contradicting
59 manufacturer directions. These views have been widely propagated on social media, and been discussed
60 and debated in recent print and televised media¹⁰⁻¹². From a virus perspective, differences in viral tropism
61 and kinetics of Omicron may be different compared to previous variants^{7,8}, and adds some credence to
62 the idea that virus may be in different parts of the respiratory system at different times.

63 Many factors can affect Ag-RDT sensitivity, including the timing and quality of specimen collection, the
64 specimen type, and the testing method itself^{13,14}. Previous work has also shown that deviating from the
65 manufacturer's instructions for rapid antigen tests can introduce errors that may yield inaccurate

66 results¹⁵. Misunderstanding erroneous test results can fuel misinformation and disinformation, ultimately
67 undermining confidence in public health efforts and trust in healthcare professionals.

68 At a low barrier volunteer-led community testing centre¹⁶, whereby samples were self-collected with
69 coaching, this work sought: to investigate whether Omicron could be detected with Ag-RDTs in
70 asymptomatic individuals; to evaluate the potential benefits of throat sampling; and assess the
71 applicability of throat sampling to other Ag-RDTs using different swabs.

72

73 **Methods**

74

75 *Sample collection and SARS-CoV-2 Ag-RDTs*

76 Participants were community members attending an urban rapid testing location available specifically for
77 those who self-identified as being asymptomatic¹⁶, over a seven-day period in January 2022. After
78 providing verbal consent, participants were verbally instructed on, and observed performing, a self-
79 collected bilateral nasal swab, and then guided on self-collection of a posterior oropharyngeal swab, with
80 the aid of an anatomical diagram of the mouth. In a second series of evaluations, participants were
81 instructed on self-swabbing for a bilateral nasal sample, followed by a combined throat/bilateral nasal
82 sample. All swabs were collected by the participants with minimal coaching by trained volunteers using
83 the Panbio COVID-19 Ag Rapid Test Device (Abbott Rapid Diagnostics, Jena, Germany) according to the
84 manufacturer's instructions. Swabs included with other Ag-RDTs differ in wand flexibility, and may have
85 different characteristics in throat sampling. Therefore, for a sub-set of participants with a positive Panbio
86 Ag-RDT (from either anatomical site), individual self-collected swabs from the anterior nares bilaterally
87 and throat were repeated and processed using the Rapid Response COVID-19 Antigen Rapid Test Device
88 (BTNX Inc., Markham, ON). All Ag-RDTs were interpreted by volunteer testing staff according to
89 manufacturer instructions, with a visualized test (T) band considered positive (in conjunction with a
90 visualized control (C) band), regardless of intensity (Figure). For supplemental results, positive reaction
91 bands were graded according to intensity relative to the control band, whereby an intensity equal to that
92 of the control band was deemed “++”, with less-intense bands as “+” and more-intense bands graded as
93 “+++”. Bands that were barely visible, were graded as “+/-”.

94

95 *SARS-CoV-2 RT-PCR*

96 Real-time RT-PCR was performed on residual test buffer (RTB) from the Ag-RDT kits to confirm positive
97 antigen detections and to investigate the possibility of false negative results¹⁶. Briefly, the remaining fluid
98 in the Ag-RDT tubes along with the used swabs for all participants (Ag-RDT positive or negative) were
99 transported to a central laboratory, and 200 µl of viral transport medial (VTM) (Rodoxica, Little Rock AR)
100 was added to each tube. Following gentle vortexing for 5 seconds, the VTM/fluid was transferred to a
101 microcentrifuge tube, and 150 µl was subjected to a total nucleic acid (TNA) extraction on a MaNAPure
102 LC 2.0 instrument (Roche Diagnostics Ltd., Roltkreuz, Switzerland), according to manufacturer instructions.
103 TNAs were eluted in a volume of 50 µl and 5 µl was used as template in a real-time RT-PCR using the
104 TaqPath COVID-19 Combo Kit (Life Technologies Corp., Frederick, MD) according to the manufacturer's
105 directions.

106

107 *Data analysis*

108 Results were defined at the level of the participant, using RT-PCR as the reference standard. Any antigen-
109 positive result from any individual's swabs confirmed by RT-PCR was considered positive. A positive Ag-
110 RDT result that failed to confirm with RT-PCR testing was interpreted as a false positive. False negative
111 Ag-RDT results were defined by detection of SARS-CoV-2 by RT-PCR in absence of an Ag-RDT positive
112 result. Concordant negative results by both Ag-RDT and RT-PCR were considered negative. Descriptive
113 statistics were used to report participation and testing outcomes, using MedCalc
114 (<http://www.medcalc.org>) where appropriate. Sensitivity and specificity were reported with 95%
115 confidence intervals (CI) for all investigations, with the exception of specificity for BTNX, which was not
116 calculated due to the lack of appropriate denominator.

117

118 **Results**

119

120 *Comparison of nasal and throat samples using Panbio Ag-RDT*

121 A total of 1568 people attended the testing site during the seven-day investigation period, of whom 1472
122 (93.9%) consented to participate. Of those who participated in the phase of separate bilateral nasal and
123 throat swabbing, 40 positive Panbio Ag-RDT results each were obtained with both the nasal and throat
124 swab, out of 62 RT-PCR-positive individuals. As such, the sensitivity for nasal or throat swabs was identical
125 at 64.5% [95% confidence interval (CI): 52.1 to 75.3%] (Table). When detections attributed to either swab
126 were combined in the same analysis, 55 of 62 individuals were identified as positive by Panbio Ag-RDT,
127 for a combined sensitivity of 88.7% [95% CI: 78.2 to 94.7%] (Table). No false positives were observed, and
128 as such, the specificity of each swab was 100% [95% CI: 99.5 to 100.0%] (Table). Of note, all RT-PCR-
129 positive samples featured an S-gene drop-out (Supplemental Tables), which is consistent with the
130 circulating Omicron VOC.

131

132 *Nasal and throat swabs comparison using the BTNX Ag-RDT*

133 To verify the generalizability of results of the Panbio Ag-RDT results, a subset of participants with a positive
134 Panbio Ag-RDT was recruited for additional testing with repeat nasal and throat swabs, which were then
135 subjected to the BTNX Rapid Response Ag-RDT. This particular assay was chosen given that the swab
136 packaged with testing device is a thin, flexible, flocked swab suitable for nasopharyngeal swabbing, in
137 contrast to the thick, rigid swabs packaged in most Ag-RDTs (like the Panbio assay). The nasal swab was
138 positive in 32/41 participants (78.1% [95% CI: 62.4 to 89.4%]) and the throat swab was positive in 26/41

139 participants (63.4% [95% CI: 46.9 to 77.9%]), but with results combined, 39/41 (95.1% [95% CI: 83.5 to
140 99.4%]) of cases were identified. No false-positive BTNX swabs were observed.

141

142 *Evaluation of a combined nasal/throat swab using Panbio*

143 After confirming the sensitivity of throat and nasal swabs alone, the performance characteristics of a
144 combined nasal/throat swab was evaluated to facilitate the practical applications of Ag-RDT sampling both
145 anatomical sites. For this phase of the quality project, participants were asked to provide a combined
146 nasal/throat swab after having completed the standard bilateral nasal swab, and each swab was subjected
147 to the Panbio Ag-RDT. A total of 520 individuals participated, of whom, 38 were positive by either
148 swabbing method. Bilateral nasal swabs resulted in 26 positive Ag-RDTs, with a sensitivity of 68.4% [95%
149 CI: 51.4 to 82.5%]. In comparison, combined nasal/throat swabbing identified 31 positive participants
150 (Figure), for a sensitivity of 81.6% [95% CI: 65.7 to 92.3%] (Table). As no false positives were detected in
151 the evaluation period, a specificity of 100% [95% CI: 99.2 to 100.0%] was obtained for both swabs.

152

153 **Discussion**

154 A global crisis such as a pandemic and the rapid dissemination of information through social media can
155 fuel perpetuation of anecdotes, misinformation, and disinformation that can hamper public health efforts
156 and trust in healthcare professionals. This quality project assessed assertions from media (social, print,
157 televised), urging the public to swab their throat in addition to (or instead of) their nares for testing with
158 Ag-RDTs. In this project, a combined collection of both nasal and throat samples increased Ag-RDT
159 sensitivity compared to the manufacturer recommended sampling of bilateral nares alone. To our
160 knowledge, this is the first report of the self-collected Ag-RDT performance of Ag-RDTs for Omicron
161 detection in an asymptomatic population.

162 Given the propensity of cold-like symptoms and complaints of sore throat during this period of high
163 prevalence of Omicron, there was likely some validity to the media accounts of false-negative nares swabs,
164 with subsequent follow-up positive throat swabs. Many of the Ag-RDTs available to the public are based
165 on nasal swabs, and are not approved for sampling saliva or the throat and previous work shows the
166 potential for invalid results when using an assay outside of the manufacturer's instructions¹⁵. Without
167 careful evaluation of this widely publicized phenomenon, variables such as test timing (and time between
168 nasal and throat tests), testing kit manufacturer, swab types, and buffers, cannot be controlled.
169 Importantly, confirmation of test results with more sensitive and specific assays (such as RT-PCR) cannot
170 be easily performed to corroborate individual anecdotes. Investigations in this work allowed for careful
171 evaluation of SARS-CoV-2 detection using Ag-RDTs, using nasal and throat swabs.

172 Prior to undertaking this evaluation, one of the primary concerns for the wide use of throat-based
173 collection for Ag-RDT testing was the potential for false positives. While food and beverages could
174 potentially impact the performance of Ag-RDTs or of molecular testing¹⁷, all of the Ag-RDT-positive throat
175 samples in this project were confirmed as positive by RT-PCR. Based on our experience with community-

176 based testing over the last year, the estimated false positive rate was between 2 and 4 per 1000
177 individuals, which is consistent with manufacturer claims. Given the widespread activity of Omicron in the
178 community, it was not surprising that few false positives were observed.

179 Apart from ensuring Ag-RDT specificity with use of a throat-based collection, understanding its potential
180 impacts on sensitivity is also crucial. The sensitivity of the Ag-RDT for Omicron detection was 82% (versus
181 RT-PCR) when using the combined nasal and throat swabs, which is on the higher end of estimates
182 previously reported for both Omicron and non-Omicron variants. The most recent Cochrane review of the
183 performance of Ag-RDTs prior to the Omicron wave suggested the sensitivity of the Panbio assay was
184 between 50% and 92%¹⁸. Although the US Food and Drug Administration (FDA) recently issued a
185 statement that antigen test may have reduced sensitivity for the detection of Omicron¹⁹, real-world data
186 was lacking. Consistent with others^{4,20}, the National Microbiology Laboratory (NML) in Canada recently
187 assessed the performance of several Ag-RDTs for Omicron detection, and results for Panbio and BTNX
188 were comparable to previous evaluations using other SARS-CoV-2 lineages (NML unpublished
189 communication).

190 The added detection from sampling the throat could be due to several factors. Sampling error or less
191 vigorous sampling of one site versus the other would influence the quality of the specimen. With the use
192 of RTB following Ag-RDT testing, molecular testing could be performed to understand SARS-CoV-2 cases
193 that would be potentially missed by Ag-RDTs using nasal and throat swab-based collections. As expected
194 for any Ag-RDT, there were false negative Ag-RDT results detected by RT-PCR, but these were equally
195 distributed between the nasal and throat-based collections. It is also possible that the discrepancy
196 between nasal and throat results is attributed to preferential replication of the Omicron variant in these
197 anatomical sites at different time points in infection. Prior to the first descriptions of Omicron, reports of
198 RT-PCR from comparisons of nasopharyngeal and oropharyngeal/nares²¹, and nasal and oropharyngeal²²
199 swabs showed little difference. On the other hand, in symptomatic non-hospitalized patients in South

200 Africa, saliva samples detected Omicron more often than mid-turbinate swabs (100% vs. 86%
201 respectively)⁸ which was opposite from the performance reported for previously circulating variants.
202 Similarly, in a pre-print non-peer reviewed publication of a small subset of individuals in a high-risk
203 occupational case cohort, the viral load in saliva specimens peaked 1 to 2 days prior to those observed
204 with nasal swab collections²³. These early data suggest there may be a different tissue tropism for the
205 Omicron variant compared to prior circulating lineages of SARS-CoV-2⁷.

206 Most individuals being tested agreed to participate, with only approximately 6% refusing, indicating that
207 a self-administered throat swab is an acceptable method for COVID-19 testing. Tolerability of throat
208 swabs and of combined nasal/throat swabs appeared to be high, without voiced concerns for swab
209 preference. Participants often performed the self-administered throat swab correctly with minimal
210 coaching. Many participants experienced a gag reflex during the self-administered throat swab, and one
211 individual vomited. This in-person volunteer observation and coaching could easily be translated to a
212 brief instructional video for at-home/occupational use.

213 This investigation is not without limitations. Our adult population is from a single centre during a seven-
214 day period, at a community testing centre. There was no collection of clinical information related to
215 patient demographics, timing from exposure, immunization history, or recent consumption of food or
216 drink. One of the criteria for attending the testing site was self-described asymptomatic status. However,
217 mild symptoms may not have been recognized as Omicron infection. Practically speaking, swabbing both
218 nasal and throat using a single swab can be done without regard for timing of symptoms or exposure, and
219 should increase rates of detection using Ag-RDTs. This is particularly important as self-directed testing and
220 management become a tool of endemic living, these data add confidence to the ability of individuals to
221 adequately perform reliable sample collection in a real-world setting.

222 Although this project focused on the Abbott Panbio Ag-RDT, the concordant results obtained using the
223 BTNX Rapid Response suggest that this enhanced detection rate using a combined swab is applicable to
224 other lateral flow tests, although further studies are warranted. While molecular confirmation with RT-
225 PCR was available, RTB is not a typical testing matrix. Despite our previous validations of RTB for this
226 application¹⁶, this approach is not as sensitive as an independent collection of swabs for RT-PCR testing
227 using dedicated transport media. As such, the sensitivity of Ag-RDTs may be overestimated in this project,
228 but this would apply to each swab type. However, not all real-world settings with vaccinated individuals
229 still aim to identify the presence of molecular viral genetic material. The use of RT-PCR in this case was to
230 provide a traditional comparison for laboratory testing purposes²⁴, that may not be relevant in a post-
231 vaccine pragmatic setting²⁵. It should be noted that the use of RTB for RT-PCR testing avoids the additional
232 nasal and throat collections for Ag-RDT and molecular testing. This work showed both the throat swab
233 alone and the combined nasal/throat swab were well accepted by participants; however, it is unclear
234 whether the same level of participation or acceptability would occur if 4 swabs were required for
235 evaluations (2 each for Ag-RDT and RT-PCR testing). Finally, as Omicron was the only SARS-CoV-2 lineage
236 circulating at the time, whole genome sequencing was not performed on the nucleic acids extracted from
237 each swab; however, all positive samples lacked amplification of the S-gene target which is consistent
238 with, but not confirmatory of detection of Omicron²⁶. This may be relevant as different variants may be
239 optimally detected with sampling of different anatomical sites, and our results are only generalizable to
240 this presumed Omicron with potential tropism differences compared to previously circulating SARS-CoV-
241 2 lineages.

242 Overall, this work provides early evidence that combined throat and bilateral nasal swabs maximize the
243 ability of Ag-RDTs to identify the Omicron variant. These types of projects are instrumental in testing
244 anecdotal reports to inform the community practice and increase confidence for those making swabbing

245 recommendations to various stakeholders and users, including asymptomatic people performing self Ag-

246 RDTs.

247

248 **Acknowledgements**

249 The authors are indebted to the community participants for this evaluation, and to the many Test to
250 Protect volunteers and coaches who have worked countless hours throughout the pandemic to ensure
251 the safety of their community and community members.

252

253 **Funding**

254 The authors declare that they have no conflicts of interest. This work received no private or public
255 funding, with the exception of the Ag-RDT kits that were provided in-kind from the government of Canada.
256 RT-PCR testing was performed by JL, with supplies provided in-kind by the Division of Microbiology,
257 Department of Pathology and Laboratory Medicine, Nova Scotia Health.

258

259 **Ethics**

260 This project was deemed a quality initiative and was therefore exempt from review by the Nova Scotia
261 Health Research Ethics Board (submission number 1027644). Specimens tested were obtained from
262 consenting participants, and all data related were provided anonymized, de-identified, and were used
263 solely with the intent to evaluate the performance characteristics of the different swab types for rapid
264 antigen testing programs used in Nova Scotia.

265

266 **Author contributions**

267 All authors were involved in the design, data acquisition, and data interpretation. GP drafted the initial
268 manuscript, with all authors contributing, and agree with the content of the final version.

269

270 **References**

- 271 1. World Health Organization. Tracking SARS-CoV-2 variants. Accessed January 16, 2022.
272 <https://www.who.int/emergencies/what-we-do/tracking-SARS-CoV-2-variants>
- 273 2. Wang L, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa.
274 *Journal of Medical Virology*. 2021;Epub ahead of print. doi:10.1002/jmv.27516
- 275 3. CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) variant — United States, December
276 1–8, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(50):1731-1734.
277 doi:10.15585/mmwr.mm7050e1
- 278 4. Deerain J, Druce J, Tran T, et al. Assessment of the analytical sensitivity of ten lateral flow devices
279 against the SARS-CoV-2 omicron variant. *J Clin Microbiol*. Published online December 22,
280 2021:jcm.02479-21. doi:10.1128/jcm.02479-21
- 281 5. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against
282 Omicron Variant in South Africa. *N Engl J Med*. Published online December 29, 2021:NEJMc2119270.
283 doi:10.1056/NEJMc2119270
- 284 6. Araf Y, Akter F, Tang Y dong, Fatemi R, Parvez Md SA, Hossain Md G. Omicron variant of SARS-CoV-
285 2: Genomics, transmissibility, and responses to current COVID-19 vaccines. *Journal of Medical*
286 *Virology*. 2022; Epub ahead of print. doi:10.1002/jmv.27588
- 287 7. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med*.
288 2021;27(5):892-903. doi:10.1038/s41591-021-01296-8
- 289 8. Marais G, Hsiao N yuan, Iranzadeh A, et al. Saliva swabs are the preferred sample for Omicron
290 detection. *MedRxiv Infectious Diseases (except HIV/AIDS)*; 2021. doi:10.1101/2021.12.22.21268246

- 291 9. Iacobucci G. Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron,
292 early data show. *BMJ*. Published online December 16, 2021:n3103. doi:10.1136/bmj.n3103
- 293 10. Magazine S, Wetzel C. Should you add a throat swab to your at-home Covid-19 test? *Smithsonian*
294 *Magazine*. Accessed January 16, 2022. [https://www.smithsonianmag.com/smart-news/should-you-](https://www.smithsonianmag.com/smart-news/should-you-add-a-throat-swab-to-your-at-home-covid-19-test-180979342/)
295 [add-a-throat-swab-to-your-at-home-covid-19-test-180979342/](https://www.smithsonianmag.com/smart-news/should-you-add-a-throat-swab-to-your-at-home-covid-19-test-180979342/)
- 296 11. Should you add a throat swab to your at-home covid test? Experts disagree. *Washington Post*.
297 <https://www.washingtonpost.com/wellness/2022/01/06/adding-throat-swab-covid-test/>. Accessed
298 January 16, 2022.
- 299 12. Are we testing wrong for Omicron? - *Wall Street Journal*. Accessed January 16, 2022.
300 [https://www.wsj.com/articles/are-throat-swabs-better-at-detecting-omicron-in-covid-19-rapid-](https://www.wsj.com/articles/are-throat-swabs-better-at-detecting-omicron-in-covid-19-rapid-tests-11641897006)
301 [tests-11641897006](https://www.wsj.com/articles/are-throat-swabs-better-at-detecting-omicron-in-covid-19-rapid-tests-11641897006)
- 302 13. Patriquin G, LeBlanc JJ. SARS-CoV-2 sensitivity limbo – How low can we go? *International Journal of*
303 *Infectious Diseases*. 2021;103:23-24. doi:10.1016/j.ijid.2020.11.138
- 304 14. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, et al. Tools and techniques for Severe Acute Respiratory
305 Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 detection. *Clin Microbiol Rev*. 2021;34(3).
306 doi:10.1128/CMR.00228-20
- 307 15. Patriquin G, Davidson RJ, Hatchette TF, et al. Generation of False-Positive SARS-CoV-2 Antigen
308 Results with Testing Conditions outside Manufacturer Recommendations: A Scientific Approach to
309 Pandemic Misinformation. *Microbiology Spectrum* 2021; 9(2):15.

- 310 16. Patriquin G, LeBlanc JJ, Williams C, et al. Comparison between nasal and nasopharyngeal swabs for
311 SARS-CoV-2 rapid antigen detection in an asymptomatic population, and direct confirmation by RT-
312 PCR from the residual buffer. [submitted] 2022.
- 313 17. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. Reliable detection of SARS-CoV-2 with
314 patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular
315 platforms. *Journal of Virological Methods*. 2021;295:114184. doi:10.1016/j.jviromet.2021.114184
- 316 18. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for
317 diagnosis of SARS-CoV-2 infection. Cochrane Infectious Diseases Group, ed. *Cochrane Database of*
318 *Systematic Reviews*. 2021;2021(4). doi:10.1002/14651858.CD013705.pub2
- 319 19. Health C for D and R. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. *FDA*. Published online
320 December 28, 2021. Accessed January 16, 2022. [https://www.fda.gov/medical-devices/coronavirus-](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests)
321 [covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests](https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests)
- 322 20. Bekliz M, Adea K, Alvarez C, et al. Analytical Sensitivity of Seven SARS-CoV-2 Antigen-Detecting
323 Rapid Tests for Omicron Variant. *MedRxiv Infectious Diseases (except HIV/AIDS)*; 2021.
324 doi:10.1101/2021.12.18.21268018
- 325 21. LeBlanc JJ, Heinsteinst C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. A combined
326 oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of
327 SARS-CoV-2. *Journal of Clinical Virology*. 2020;128:104442. doi:10.1016/j.jcv.2020.104442
- 328 22. Li M, Wei R, Yang Y, et al. Comparing SARS-CoV-2 testing in anterior nasal vestibular swabs vs.
329 oropharyngeal swabs. *Front Cell Infect Microbiol*. 2021;11:653794. doi:10.3389/fcimb.2021.653794

- 330 23. Adamson B, Sikka R, Wyllie AL, Premrurit P. Discordant SARS-CoV-2 PCR and rapid antigen test
331 results when infectious: A December 2021 occupational case series. *MedRxiv Infectious Diseases*
332 *(except HIV/AIDS)*; 2022. doi:10.1101/2022.01.04.22268770
- 333 24. Dinnes J. COVID-19 rapid antigen testing strategies require careful evaluation. *EBioMedicine*.
334 2021;70:103491. doi:10.1016/j.ebiom.2021.103491
- 335 25. Petersen I, Crozier A, Buchan I, Mina MJ, Bartlett JW. Recalibrating SARS-CoV-2 antigen rapid lateral
336 flow test relative sensitivity from validation studies to absolute sensitivity for indicating individuals
337 shedding transmissible virus. *CLEP*. 2021;Volume 13:935-940. doi:10.2147/CLEP.S311977
- 338 26. Metzger CMJA, Lienhard R, Seth-Smith HMB, et al. PCR performance in the SARS-CoV-2 Omicron
339 variant of concern? *Swiss Med Wkly*. 2021;151(49-50). doi:10.4414/smw.2021.w30120

340

341


342 **Table. Sensitivity and specificity of sampling different anatomical sites for SARS-CoV-2 detection by**
343 **antigen-based rapid detection tests.**

Test	Swab type	Sensitivity	95% CI	Specificity	95% CI
Abbott Panbio	Nasal alone	64.5%	52.1 to 75.3%	100.0%	99.5 to 100.0%
	Throat alone	64.5%	52.1 to 75.3%	100.0%	99.5 to 100.0%
	Combined results	88.7%	78.2 to 94.7%	100.0%	99.5 to 100.0%
BTNX Rapid Response	Nasal alone	78.1%	62.4 to 89.4%	NA	NA
	Throat alone	63.4%	46.9 to 77.9%	NA	NA
	Combined results	95.1%	83.5 to 99.4%	NA	NA
Abbott Panbio	Nasal alone	68.4%	51.4 to 82.5%	100.0%	99.2 to 100.0%
	Combined nasal + throat swab	81.6%	65.7 to 92.3%	100.0%	99.2 to 100.0%

344

345 CI, confidence interval; NA, not applicable

346



347

348 **Figure.** Representative example of a single participant's results using the Abbott Panbio antigen-based
349 rapid testing device, for (A) nasal sampling alone, and (B) combined nasal/throat sampling. Bands
350 represent the control line (C) and test line (T), indicating a negative result for A and the detection of
351 SARS-CoV-2 for B.

352

353 **Supplemental Table 1. Nasal vs. Throat (Panbio)**

Participant number	Nasal						Throat					
	Panbio		Taqpath				Panbio		Taqpath			
	Result	Score	N	Orf1a	S	Result	Result	Score	N	Orf1a	S	Result
1	POS	+	29.48	29.13	NEG	POS	NEG	NEG	35.13	35.07	NEG	POS
2	NEG	NEG	34.17	33.17	NEG	POS	POS	++	30.19	30.03	NEG	POS
3	POS	+	31.68	30.66	NEG	POS	POS	+++	29.18	28.83	NEG	POS
4	NEG	NEG	35.18	35.23	NEG	POS	POS	+/-	31.01	30.78	NEG	POS
5	POS	+++	21.32	20.2	NEG	POS	NEG	NEG	33.69	31.31	NEG	POS
6	POS	++	30.63	29.59	NEG	POS	NEG	NEG	35.41	34.57	NEG	POS
7	POS	+/-	30.28	30.64	NEG	POS	POS	++	28.54	28.38	NEG	POS
8	NEG	NEG	33.34	33.86	NEG	POS	POS	++	29.35	29.78	NEG	POS
9	NEG	NEG	34.82	34.06	NEG	POS	POS	+	33.56	34.06	NEG	POS
10	POS	+	29.35	29.78	NEG	POS	POS	++	27.54	27.49	NEG	POS
11	POS	+++	20.34	19.87	NEG	POS	POS	+++	18.98	19.17	NEG	POS
12	POS	+	30.08	29.74	NEG	POS	NEG	NEG	33.48	33.22	NEG	POS
13	POS	+++	27.09	26.61	NEG	POS	POS	+++	27.69	27.44	NEG	POS
14	POS	++	28.94	28.17	NEG	POS	POS	+	31.98	31.16	NEG	POS
15	POS	++	30.28	30.03	NEG	POS	NEG	NEG	36.68	NEG	NEG	POS
16	NEG	NEG	34.12	33.68	NEG	POS	POS	++	29.32	32.33	NEG	POS
17	POS	++	28.87	29.01	NEG	POS	NEG	NEG	29.62	29.41	NEG	POS
18	POS	++	23.92	23.66	NEG	POS	POS	+++	25.21	25.43	NEG	POS
19	NEG	NEG	37.84	37.04	NEG	POS	POS	+++	29.6	30.67	NEG	POS
20	NEG	NEG	36.18	36.08	NEG	POS	POS	+++	30.64	30.94	NEG	POS
21	POS	+	31.66	31.61	NEG	POS	POS	++	31.23	33.85	NEG	POS
22	POS	+++	26.01	25.86	NEG	POS	POS	+/-	32.67	32.18	NEG	POS
23	POS	+++	30.33	30.14	NEG	POS	NEG	NEG	31.31	30.49	NEG	POS
24	POS	+	32.21	33.25	NEG	POS	POS	++	27.61	27.16	NEG	POS
25	POS	++	30.03	30.21	NEG	POS	POS	+	33.54	33.63	NEG	POS
26	NEG	NEG	31.61	30.5	NEG	POS	POS	++	31.04	30.21	NEG	POS
27	POS	+	32.83	32.91	NEG	POS	POS	+++	28.80	28.65	NEG	POS
28	POS	++	26.99	26.49	NEG	POS	POS	+	28.12	28.13	NEG	POS
29	NEG	NEG	35.46	38.94	NEG	POS	POS	+++	29.05	30.09	NEG	POS
30	POS	+++	25.41	25.51	NEG	POS	POS	+/-	33.12	33.02	NEG	POS
31	POS	+++	27.48	28.72	NEG	POS	NEG	NEG	33.41	34.42	NEG	POS
32	NEG	NEG	33.36	34.07	NEG	POS	POS	++	31.30	32.04	NEG	POS
33	NEG	NEG	33.92	36.32	NEG	POS	POS	+	31.23	33.09	NEG	POS
34	NEG	NEG	33.36	34.07	NEG	POS	POS	+	31.3	32.04	NEG	POS
35	POS	+++	28.38	29.15	NEG	POS	NEG	NEG	33.19	34.33	NEG	POS
36	POS	++	24.14	25.63	NEG	POS	POS	++	25.26	25.59	NEG	POS
37	POS	+/-	32.43	33.10	NEG	POS	NEG	NEG	33.45	34.90	NEG	POS
38	POS	+	28.02	29.11	NEG	POS	NEG	NEG	31.92	32.98	NEG	POS
39	NEG	NEG	31.63	33.01	NEG	POS	POS	+	27.8	28.97	NEG	POS

40	POS	++	31.81	32.32	NEG	POS		NEG	NEG	31.12	31.98	NEG	POS
41	POS	+++	23.23	23.66	NEG	POS		NEG	NEG	32.47	33.15	NEG	POS
42	POS	+++	23.70	24.65	NEG	POS		POS	+	31.17	32.56	NEG	POS
43	POS	+++	28.14	29.42	NEG	POS		POS	+/-	31.08	35.53	NEG	POS
44	POS	++	28.79	29.83	NEG	POS		NEG	NEG	32.41	33.02	NEG	POS
45	POS	+	31.57	33.62	NEG	POS		POS	+	31.12	32.23	NEG	POS
46	POS	+	28.77	29.13	NEG	POS		POS	+++	28.43	29.17	NEG	POS
47	POS	+++	20.23	20.65	NEG	POS		POS	+++	30.09	32.64	NEG	POS
48	POS	++	26.50	27.07	NEG	POS		POS	+++	21.39	21.78	NEG	POS
49	POS	++	27.16	27.36	NEG	POS		POS	+++	27.15	27.83	NEG	POS
50	POS	+	31.11	31.49	NEG	POS		NEG	NEG	33.41	34.87	NEG	POS
51	POS	++	26.12	26.26	NEG	POS		POS	+/-	31.1	33.17	NEG	POS
52	NEG	NEG	32.82	33.01	NEG	POS		POS	+	29.73	30.13	NEG	POS
53	POS	+++	27.01	27.92	NEG	POS		POS	+++	27.66	28.64	NEG	POS
54	NEG	NEG	32.17	33.15	NEG	POS		POS	+/-	30.83	31.15	NEG	POS
55	POS	++	27.96	28.49	NEG	POS		POS	+	31.8	32.78	NEG	POS
56	NEG	NEG	30.61	31.07	NEG	POS		NEG	NEG	36.68	37.03	NEG	POS
57	NEG	NEG	32.80	33.44	NEG	POS		NEG	NEG	34.14	36.16	NEG	POS
58	NEG	NEG	34.99	36.4	NEG	POS		NEG	NEG	34.12	36.72	NEG	POS
59	NEG	NEG	NEG	NEG	NEG	NEG		NEG	NEG	30.45	30.7	NEG	POS
60	NEG	NEG	NEG	NEG	NEG	NEG		NEG	NEG	29.54	30.24	NEG	POS
61	NEG	NEG	NEG	NEG	NEG	NEG		NEG	NEG	NEG	35.56	NEG	POS
62	NEG	NEG	NEG	NEG	NEG	NEG		NEG	NEG	35.86	NEG	NEG	POS
Negatives (n=763)	NEG	NEG	NEG	NEG	NEG	NEG		NEG	NEG	NEG	NEG	NEG	NEG

354

355

356 **Supplemental Table 2. Nasal vs. Throat (BTNX)**

Participant number	Nasal						Throat					
	BTNX		Taqpath				BTNX		Taqpath			
	Result	Score	N	Orf1a	S	Result	Result	Score	N	Orf1a	S	Result
1	NEG	NEG	32.08	33.11	NEG	POS	POS	++	26.49	27.02	NEG	POS
2	NEG	NEG	33.41	34.14	NEG	POS	POS	++	31.82	32.26	NEG	POS
3	POS	++	27.96	28.54	NEG	POS	POS	+/-	31.05	32.00	NEG	POS
4	POS	+	31.34	32.84	NEG	POS	NEG	NEG	27.71	28.56	NEG	POS
5	POS	++	29.20	29.11	NEG	POS	NEG	NEG	27.43	28.05	NEG	POS
6	POS	++	28.88	29.28	NEG	POS	NEG	NEG	33.00	34.12	NEG	POS
7	POS	+	28.96	30.36	NEG	POS	NEG	NEG	37.88	NEG	NEG	NEG
8	POS	+	31.68	33.17	NEG	POS	POS	+	32.83	34.06	NEG	POS
9	POS	+	26.62	27.07	NEG	POS	NEG	NEG	29.63	30.57	NEG	POS
10	POS	+	25.27	25.55	NEG	POS	POS	++	28.31	29.18	NEG	POS
11	POS	++	29.39	30.57	NEG	POS	POS	+	31.02	31.89	NEG	POS
12	POS	++	28.34	29.15	NEG	POS	POS	++	29.43	30.68	NEG	POS
13	NEG	NEG	32.80	33.76	NEG	POS	POS	+	31.29	31.13	NEG	POS
14	POS	+	29.18	29.69	NEG	POS	POS	+/-	28.13	28.63	NEG	POS
15	NEG	NEG	37.12	36.91	NEG	POS	POS	++	22.85	23.77	NEG	POS
16	POS	++	24.92	25.51	NEG	POS	POS	+	31.38	33.16	NEG	POS
17	POS	+	31.33	33.09	NEG	POS	POS	NEG	34.03	35.88	NEG	POS
18	NEG	NEG	30.87	30.91	NEG	POS	POS	++	27.81	28.12	NEG	POS
19	POS	+/-	32.30	32.47	NEG	POS	POS	++	21.49	21.73	NEG	POS
20	POS	+	32.45	31.87	NEG	POS	POS	+/-	28.94	29.63	NEG	POS
21	NEG	NEG	31.84	31.98	NEG	POS	POS	+	29.04	28.82	NEG	POS
22	POS	+	26.91	26.96	NEG	POS	POS	+/-	27.53	27.61	NEG	POS
23	POS	++	27.37	27.55	NEG	POS	NEG	NEG	31.04	31.77	NEG	POS
24	POS	+/-	32.85	32.54	NEG	POS	POS	++	28.3	28.96	NEG	POS
25	POS	+/-	28.82	29.41	NEG	POS	POS	++	26.16	27.39	NEG	POS
26	NEG	NEG	37.12	36.13	NEG	POS	NEG	NEG	36.87	37.10	NEG	POS
27	POS	++	26.90	27.08	NEG	POS	NEG	NEG	34.23	34.67	NEG	POS
28	POS	++	25.22	26.06	NEG	POS	NEG	NEG	29.87	30.37	NEG	POS
29	POS	++	24.49	24.19	NEG	POS	NEG	NEG	33.23	33.56	NEG	POS
30	POS	++	26.12	26.62	NEG	POS	POS	+	29.73	30.1	NEG	POS
31	POS	++	27.93	28.76	NEG	POS	POS	++	28.85	29.71	NEG	POS
32	POS	+	31.41	31.78	NEG	POS	NEG	NEG	36.89	35.97	NEG	POS
33	POS	+/-	33.13	34.20	NEG	POS	NEG	NEG	34.15	34.46	NEG	POS
34	POS	+	31.72	32.49	NEG	POS	POS	+	32.63	32.26	NEG	POS
35	POS	++	28.78	30.01	NEG	POS	POS	++	30.63	31.52	NEG	POS
36	POS	+	34.88	35.96	NEG	POS	NEG	NEG	NEG	NEG	NEG	NEG
37	POS	++	21.44	21.68	NEG	POS	POS	++	20.59	30.74	NEG	POS
38	POS	++	25.63	25.54	NEG	POS	POS	+/-	34.47	34.67	NEG	POS
39	POS	++	30.95	30.30	NEG	POS	NEG	NEG	NEG	NEG	NEG	NEG

40	NEG	NEG	33.13	33.66	NEG	POS		NEG	NEG	NEG	NEG	NEG	NEG
41	NEG	NEG	32.57	32.37	NEG	POS		POS	+	24.57	24.65	NEG	POS

357

358

359

360 **Supplemental Table 3. Nasal sample vs. Throat + Nasal combo swab (Panbio)**

Participant number	Nasal						Nasal/throat					
	Panbio		Taqpath				Panbio		Taqpath			
	Result	Score	N	Orf1a	S	Result	Result	Score	N	Orf1a	S	Result
1	NEG	NEG	35.45	NEG	NEG	POS	POS	++	26.43	27.01	NEG	POS
2	POS	++	25.78	26.21	NEG	POS	POS	++	25.91	26.67	NEG	POS
3	POS	+++	17.24	17.74	NEG	POS	POS	+++	24.18	24.86	NEG	POS
4	POS	+	29.63	30.88	NEG	POS	POS	+	32.25	32.51	NEG	POS
5	NEG	NEG	33.12	33.69	NEG	POS	POS	++	27.67	28.07	NEG	POS
6	POS	+++	18.91	19.77	NEG	POS	POS	+++	25.36	25.89	NEG	POS
7	POS	+/-	32.35	34.02	NEG	POS	POS	+/-	29.88	30.21	NEG	POS
8	POS	++	24.12	24.65	NEG	POS	POS	+++	20.64	21.63	NEG	POS
9	POS	+	29.81	30.08	NEG	POS	POS	+	29.62	29.97	NEG	POS
10	POS	+/-	34.32	34.71	NEG	POS	POS	+/-	33.82	NEG	NEG	POS
11	POS	+/-	33.87	34.27	NEG	POS	POS	+/-	34.16	35.64	NEG	POS
12	POS	++	31.12	30.94	NEG	POS	POS	++	28.28	28.32	NEG	POS
13	POS	+++	21.83	21.68	NEG	POS	POS	++	24.52	24.82	NEG	POS
14	POS	+++	19.75	19.71	NEG	POS	POS	+++	19.42	19.37	NEG	POS
15	POS	+	31.11	31.08	NEG	POS	POS	+	31.58	31.79	NEG	POS
16	POS	++	30.76	31.20	NEG	POS	POS	++	29.35	29.70	NEG	POS
17	POS	++	26.98	26.87	NEG	POS	POS	+	28.79	28.89	NEG	POS
18	POS	+++	24.28	24.33	NEG	POS	POS	+++	22.70	22.64	NEG	POS
19	POS	+	31.87	31.78	NEG	POS	POS	+	31.03	31.11	NEG	POS
20	POS	+	30.57	30.73	NEG	POS	POS	+	30.24	30.62	NEG	POS
21	POS	+++	25.63	25.95	NEG	POS	POS	+++	25.16	25.09	NEG	POS
22	NEG	NEG	32.65	32.83	NEG	POS	POS	+	30.68	31.14	NEG	POS
23	NEG	NEG	NEG	NEG	NEG	NEG	POS	+++	25.22	25.59	NEG	POS
24	POS	+++	25.27	25.32	NEG	POS	POS	+++	24.31	24.98	NEG	POS
25	POS	+++	27.01	27.12	NEG	POS	POS	++	26.94	27.05	NEG	POS
26	POS	+++	25.10	25.01	NEG	POS	POS	+++	26.06	26.80	NEG	POS
27	POS	+/-	33.28	35.17	NEG	POS	POS	+/-	32.38	34.69	NEG	POS
28	POS	+++	27.31	25.89	NEG	POS	POS	+++	27.24	26.50	NEG	POS
29	POS	++	30.38	30.25	NEG	POS	POS	+	30.95	30.30	NEG	POS
30	POS	+	31.29	32.2	NEG	POS	POS	NEG	33.51	34.30	NEG	POS
31	NEG	NEG	34.25	35.25	NEG	POS	POS	++	24.77	24.68	NEG	POS
32	NEG	N/A	NEG	NEG	NEG	NEG	NEG	N/A	30.79	31.25	NEG	POS
33	NEG	N/A	35.77	NEG	NEG	POS	NEG	N/A	32.31	33.14	NEG	POS
34	NEG	N/A	34.51	NEG	NEG	POS	NEG	N/A	NEG	NEG	NEG	NEG
35	NEG	N/A	34.73	NEG	NEG	POS	NEG	N/A	NEG	NEG	NEG	NEG
36	NEG	N/A	NEG	NEG	NEG	NEG	NEG	N/A	35.44	35.83	NEG	POS
37	NEG	N/A	NEG	NEG	NEG	NEG	NEG	N/A	33.64	34.67	NEG	POS
38	NEG	N/A	35.22	35.02	NEG	POS	NEG	N/A	NEG	NEG	NEG	NEG

Negatives (n=482)	NEG	N/A	NEG	NEG	NEG	NEG		NEG	N/A	NEG	NEG	NEG	NEG
----------------------	-----	-----	-----	-----	-----	-----	--	-----	-----	-----	-----	-----	-----

361

362

363